The HudsonAlpha Institute for Biotechnology wrapped up its contributions to the American Society for Human Genetics annual meeting on Friday with one final presentation.
Ryne Ramaker, PhD, a recent MD/PhD student in the Sara Cooper Lab gave a platform presentation on high-throughput identification of genes involved in single and multi-drug resistance in pancreatic cancer using pooled CRISPR screening. The researchers involved in the study utilized genome-wide CRISPR activation and CRISPR knock-out. With those tools, they generated a resource capable of nominating important mechanisms of drug resistance and predicting response to chemotherapy for pancreatic ductal adenocarcinoma (PDAC) cell lines and tumors. These discoveries resulted from a collaboration between Ryne Ramaker and Drew Hardigan, PhD, a recent MD/PhD student in the Myers Lab.
Ramaker’s talk concludes a series of contributions to the conference including multiple posters, a presentation and a panel session.
“We always welcome the chance to show other researchers what we’re working on,” said HudsonAlpha Faculty Chair Greg Barsh, MD, PhD, “We’re proud of what we were able to bring to ASHG this year.”
